公共卫生
控制(管理)
药物管制
药品
非法药物
风险分析(工程)
精神活性物质
业务
医学
环境卫生
互联网隐私
药理学
计算机科学
精神科
人工智能
护理部
作者
Amy Peacock,Raimondo Bruno,Natasa Gisev,Louisa Degenhardt,Wayne Hall,Roumen Sedefov,Jason M. White,Kevin V. Thomas,Michael Farrell,Paul Griffiths
出处
期刊:The Lancet
[Elsevier BV]
日期:2019-10-23
卷期号:394 (10209): 1668-1684
被引量:352
标识
DOI:10.1016/s0140-6736(19)32231-7
摘要
The rapid emergence since the mid-2000s of a large and diverse range of substances originally designed as legal alternatives to more established illicit drugs (pragmatically clustered and termed new psychoactive substances; [NPS]) has challenged traditional approaches to drug monitoring, surveillance, control, and public health responses. In this section of the Series, we describe the emergence of NPS and consider opportunities for strengthening the detection, identification, and responses to future substances of concern. First, we explore the definitional complexity of the term NPS. Second, we describe the origins and drivers surrounding NPS, including motivations for use. Third, we summarise evidence on NPS availability, use, and associated harms. Finally, we use NPS as a case example to explore challenges and opportunities for future drug monitoring, surveillance, control, and public health responses. We posit that the current means of responding to emerging substances might no longer be fit for purpose in a world in which different substances can be rapidly introduced, and where people who use drugs can change preferences on the basis of market availability.
科研通智能强力驱动
Strongly Powered by AbleSci AI